JAK1 Inhibition during CAR-T Cell Treatment Results in Reduction in Various Cytokines That Correlate with Cytokine Release Syndrome (CRS) and Immune Effector Cell (IEC) –Associated Neurotoxicity Syndrome (ICANS) Grades

Prophylactic treatment with itacitinib (ITA), a potent, selective oral Janus kinase (JAK)1 inhibitor, to manage onset and severity of cytokine release syndrome (CRS) and immune effector cell –associated neurotoxicity syndrome (ICANS) in response to CAR-T infusion was evaluated in the phase 2 study INCB 39110-211 (NCT04071366). The study had 2 parts: part 1 included patients treated with ITA 200 mg once daily (QD); part 2 was randomized and double-blind and evaluated ITA 200 mg twice d aily (BID) vs placebo.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Michael Pratta, Angelina Volkova, John F. DiPersio, Richard T. Maziarz, Aleksandr Lazaryan, Patricia Feldman, Cynthia Timmers, Lea Burke, Olga Ivanova, Rodica Morariu-Zamfir, Matthew J. Frigault Tags: 236 Source Type: research